Type to search

News

Delaware-based Incyte signs research deal with Dutch company

Avatar photo
Share

WILMINGTON (AP) — Wilmington-based biopharmaceutical company Incyte has signed a $200 million research deal with a Dutch company that experts say could lead to an expansion of its Delaware operations.

According to The News Journal, Incyte will pay about $120 million to Merus, a Dutch developer of cancer medicines. The company will also spend $80 million to buy Merus stock. That will help the company access 11 of Merus’ products.

Experts say having access to the additional medicines could mean Incyte will hire more people to work on them.

According to the newspaper, the company already employees 680 workers in its Delaware operations.

Get the free DBT email newsletter  

Follow the people, companies and issues that matter most to business in Delaware.

You Might also Like

Leave a Comment

Your email address will not be published. Required fields are marked *

Premier Digital Partners

© 2024 Delaware Business Times

Flash Sale! Subscribe to Delaware Business Times and save 50%.

Limited time offer. New subscribers only.

Limited time offer. New subscribers only.

SUMMER FLASH SALE!

Subscribe to Delaware Business Times and save 50%